Metsera falls after accepting up to $10 billion offer from Pfizer

By Mariam Sunny (Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.
Zacks.com on MSN

Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

NVO: Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera

Novo Nordisk (NYSE:NVO) climbs about 2% on early Monday after it says it will not raise its offer for Metsera (NASDAQ:MTSR), ...

Pfizer wins obesity drug prize, with Trump administration assist

Pfizer Inc. chief executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Novo Nordisk shares rise on investor relief after it exits Metsera bid

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion ...

S&P 500 Futures Up in Premarket Trading; monday.com, Metsera Lag

With U.S. stock markets set to open in two hours, Maplebear Inc. (CART) was up 8.1% in pre-market trading, and Caris Life Sciences Inc. (CAI) was up 7.3%.